Sublocade (buprenorphine) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to treat opioid use disorder in adults, as part of a complete treatment ...
RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...
Sublocade (buprenorphine) and Suboxone (buprenorphine/naloxone) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat opioid use disorder (OUD).
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
Indivior recently released results from a multicenter, open-label clinical trial showing that rapid induction with SUBLOCADE, using a single 4 mg oral buprenorphine dose followed by a same-day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback